WO2024100682A1 - Sustained release composition of hydroxyzine and it's process - Google Patents
Sustained release composition of hydroxyzine and it's process Download PDFInfo
- Publication number
- WO2024100682A1 WO2024100682A1 PCT/IN2023/051037 IN2023051037W WO2024100682A1 WO 2024100682 A1 WO2024100682 A1 WO 2024100682A1 IN 2023051037 W IN2023051037 W IN 2023051037W WO 2024100682 A1 WO2024100682 A1 WO 2024100682A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxyzine
- sustained release
- dosage form
- pharmaceutically acceptable
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical group C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 229960000930 hydroxyzine Drugs 0.000 title claims abstract description 43
- 238000013268 sustained release Methods 0.000 title claims abstract description 26
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 19
- 230000008569 process Effects 0.000 title description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 239000007888 film coating Substances 0.000 claims abstract description 26
- 238000009501 film coating Methods 0.000 claims abstract description 26
- 239000011248 coating agent Substances 0.000 claims abstract description 24
- 230000004888 barrier function Effects 0.000 claims abstract description 23
- 238000000576 coating method Methods 0.000 claims abstract description 23
- 239000011159 matrix material Substances 0.000 claims abstract description 15
- 206010039897 Sedation Diseases 0.000 claims abstract description 8
- 230000036280 sedation Effects 0.000 claims abstract description 8
- 229920000642 polymer Polymers 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 26
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 24
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 21
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 19
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 19
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 19
- 239000003826 tablet Substances 0.000 claims description 19
- 239000011230 binding agent Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 16
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 16
- 239000003085 diluting agent Substances 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 238000004090 dissolution Methods 0.000 claims description 13
- 229960003943 hypromellose Drugs 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 239000003607 modifier Substances 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 12
- 239000000314 lubricant Substances 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 239000011148 porous material Substances 0.000 claims description 12
- 239000001856 Ethyl cellulose Substances 0.000 claims description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 229920001249 ethyl cellulose Polymers 0.000 claims description 9
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 7
- 230000001624 sedative effect Effects 0.000 claims description 7
- 238000003801 milling Methods 0.000 claims description 6
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 5
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000008185 minitablet Substances 0.000 claims description 5
- 230000036470 plasma concentration Effects 0.000 claims description 5
- 229920001531 copovidone Polymers 0.000 claims description 4
- 238000007580 dry-mixing Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000001050 lubricating effect Effects 0.000 claims description 4
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 4
- 239000011118 polyvinyl acetate Substances 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 239000004800 polyvinyl chloride Substances 0.000 claims description 3
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims 7
- 229960003220 hydroxyzine hydrochloride Drugs 0.000 abstract description 18
- 238000002360 preparation method Methods 0.000 abstract description 8
- 239000012453 solvate Substances 0.000 abstract description 8
- 239000007939 sustained release tablet Substances 0.000 description 22
- 238000009472 formulation Methods 0.000 description 17
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000013543 active substance Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 6
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 6
- 229960001021 lactose monohydrate Drugs 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 238000007907 direct compression Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003113 alkalizing effect Effects 0.000 description 2
- 229940065779 atarax Drugs 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical class [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- -1 hydrochloric Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JCYZKOJFYMJJTJ-UHFFFAOYSA-N 2-(2-piperazine-1,4-diium-1-ylethoxy)ethanol;dichloride Chemical compound Cl.Cl.OCCOCCN1CCNCC1 JCYZKOJFYMJJTJ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012373 Depressed level of consciousness Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- 229920003159 Eudragit® RS 100 Polymers 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 229910002054 SYLOID® 244 FP SILICA Inorganic materials 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229920001893 acrylonitrile styrene Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940031576 hydroxypropylbetadex (0.58-0.68 ms) Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940079707 vistaril Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Definitions
- the present invention relates to sustained release compositions of Hydroxyzine or a pharmaceutically acceptable salt or a solvate thereof.
- the present invention also relates to sustained release compositions of Hydroxyzine hydrochloride comprising core matrix, barrier coating and film coating with less sedation.
- the invention also relates to a method of preparation of such compositions of Hydroxyzine or pharmaceutically acceptable salts or solvate thereof.
- Hydroxyzine (hye drox' i zeen) is a first generation antihistamine that is used mostly to treat itching and nausea. Because of its sedating effects, hydroxyzine is also used for anxiety, tension and as a mild sleeping aid. Hydroxyzine belongs to the piperazine class of antihistamines (with cyclizine and meclizine) which are more commonly used for itching, nausea and anxiety than for their effects on symptoms of allergic rhinitis or coryza. Hydroxyzine was approved for use in the United States in 1956 and continues to be widely used. It is available as tablet and capsule dosage forms of 10, 25, 50 and 100 mg under the trade names Atarax and Vistaril.
- Hydroxyzine hydrochloride is chemically known as l-(p- chlorobenzhydryl) 4-[2-(2-hydroxyethoxy)-ethyl] piperazine dihydrochloride with the chemical formula C21H27CIN2O2 • 2HC1, molecular weight of 447.83 g/mol and has the following chemical structure:
- U.S. Patent No. 3,577,514A discloses sustained release pharmaceutical tablet composition of Hydroxyzine characterized by a substantially constant rate of drug release comprising; (a) medicament; (b) a hydrophobic dissolution retardant; (c) an acid-insoluble release agent; and (d) a water-soluble or dispersible binder.
- WO 2001/051033 Al discloses solid pharmaceutical composition for oral administration, allowing controlled release by at least one active substance, consisting of a homogeneous mixture including: a) said at least one substance; b) between 5 and 95% by weight, relative to the total weight of the composition, of at least one matrix excipient; c) between 2 and 50% by weight, relative to the total weight of the composition, of at least one enteric-soluble polymer; and d) between 0.5 and 50% by weight, relative to the total weight of the composition, of at least an alkalizing agent soluble in an aqueous phase under pH conditions physiological.
- This publication discloses Hydroxyzine as a substance in a laundry list.
- U.S. Publication No. 2021/0228488 Al discloses an extended release pharmaceutical composition comprising plurality of modified release units wherein each unit comprises of an active agent core comprising at least one pharmaceutically active agent and at least one pharmaceutically acceptable excipient, substantially coated with at least one releasecontrolling agent. Hydroxyzine is disclosed as active agent.
- sustained release pharmaceutical compositions comprising medicament (Hydroxyzine), hydrophobic dissolution retardant, an acid-insoluble release agent, a water-soluble or dispersible binder, controller release formulation comprising substance, matrix excipient, enteric-soluble polymer, alkalizing agent, extended release pharmaceutical composition comprising plurality of modified release units, hydroxyzine hydrochloride sustained release microspheres.
- medicament Hydrophobic dissolution retardant
- an acid-insoluble release agent e.g., a water-soluble or dispersible binder
- controller release formulation comprising substance, matrix excipient, enteric-soluble polymer, alkalizing agent
- extended release pharmaceutical composition comprising plurality of modified release units, hydroxyzine hydrochloride sustained release microspheres.
- inventors of the present invention have developed sustained release oral composition of Hydroxyzine or its pharmaceutically acceptable salt. Further, the inventors of the present invention provide sustained release tablet composition of Hydroxyzine hydrochloride which is targeted to release the drug with blunted Cmax with plasma concentration values ranging between 40 ⁇ 12 ng/mL, thus the formulation of the present invention has a potential to reduce the exposure to high levels of the drug, while maintaining the efficacy. The inventors of the present invention also provide method of preparation of sustained release tablet composition of Hydroxyzine or its pharmaceutically acceptable salts using wet granulation and direct compression.
- the main aspect of the present invention is to provide sustained release oral pharmaceutical compositions of Hydroxyzine or its pharmaceutically acceptable salt or a solvate thereof with less sedative effect.
- the present invention relates to sustained release oral pharmaceutical compositions comprising Hydroxyzine or its pharmaceutically acceptable salts as active ingredient along with other pharmaceutically acceptable excipients.
- the present invention relates to the oral pharmaceutical compositions of the present invention include tablets, capsules, mini-tablets, granules.
- the present invention relates to sustained release tablet composition of Hydroxyzine or its pharmaceutically acceptable salt comprising a) core matrix, b) barrier coating and c) film coating.
- the present invention relates to sustained release tablet composition
- sustained release tablet composition comprising Hydroxyzine or its pharmaceutically acceptable salt, high viscosity polymers, diluents, binder, filler, glidant, water-insoluble release modifier, pore forming agent, lubricant, solvents as pharmaceutically acceptable excipients.
- the present invention relates to sustained release tablet composition of Hydroxyzine or its pharmaceutically acceptable salt comprising a) core matrix containing active ingredient, high viscosity polymers, diluent, binder, glidant, lubricant, solvents, b) barrier coating containing water-insoluble release modifier, pore forming agent, solvents and c) film coating containing opadry film coating and solvent.
- In yet another aspect of the present invention relates to process for the preparation of sustained release tablet composition of Hydroxyzine or its pharmaceutically acceptable salt comprising the steps of sifting, wet granulation, drying, milling, blending, lubrication, direct compression, barrier coating, film coating and packing.
- a sustained release composition of Hydroxyzine or its pharmaceutically acceptable salt which is targeted to release the drug with blunted Cmax with plasma concentration values ranging between 40 ⁇ 12 ng/mL, thus has a potential to reduce the exposure to high levels of the molecule, while still maintaining efficacy.
- compositions of the present invention when subjected to in vitro changeover dissolution study exhibits following release profile: i) releases not more than 35% in 1 hour, in 900 ml of 0.01N HC1 medium at 50 rpm and 37°C using USP type II apparatus, and ii) releases at least about 40% - 85% in 4 hours and not less than 85% in 10 hours, in 900 ml of pH 6.8 phosphate buffer medium at 50 rpm and 37°C using USP type II apparatus.
- the present invention relates to sustained release tablet of Hydroxyzine or a pharmaceutically acceptable salt or a solvate thereof to overcome the side effects associated with Hydroxyzine Hydrochloride immediate release tablet.
- the present invention relates to sustained release oral pharmaceutical compositions comprising Hydroxyzine or its pharmaceutically acceptable salts as active ingredient along with other pharmaceutically acceptable excipients.
- the present invention relates to the oral pharmaceutical compositions of the present invention include tablets, capsules, mini-tablets, granules.
- the present invention relates to sustained release tablet composition
- sustained release tablet composition comprising Hydroxyzine or a pharmaceutically acceptable salt as active ingredient and pharmaceutically acceptable excipients.
- the present invention relates to sustained release tablet composition
- sustained release tablet composition comprising Hydroxyzine or a pharmaceutically acceptable salt as active ingredient, high viscosity polymers, diluents, binder, filler, glidant, water-insoluble release modifier, pore forming agent, lubricant, solvents as pharmaceutically acceptable excipients.
- the present invention relates to sustained release tablet composition
- sustained release tablet composition comprising a) core matrix, b) barrier coating and c) film coating.
- the present invention relates to sustained release tablet composition of Hydroxyzine or a pharmaceutically acceptable salt comprising a) core matrix comprising active ingredient, high viscosity polymers, diluent, binder, glidant, lubricant, solvents, b) barrier coating comprising water-insoluble release modifier, pore forming agent, solvents and c) film coating comprising opadry film coating and solvent.
- the present invention relates to sustained release tablet composition of Hydroxyzine or a pharmaceutically acceptable salt
- Another aspect of the present invention relates to provide process for the preparation of oral sustained release pharmaceutical compositions of Hydroxyzine or its pharmaceutically acceptable salts.
- Another aspect of the present invention relates to provide process for the preparation of sustained release tablet composition of Hydroxyzine hydrochloride comprising the steps of dispensing, sifting, wet granulation, drying, milling, blending, lubrication, direct compression, barrier coating, film coating and packing.
- the present invention relates to sustained release tablet composition
- sustained release tablet composition comprising: a) core matrix:
- the present invention relates to sustained release tablet composition Hydroxyzine hydrochloride comprising: a) core matrix:
- magnesium stearate 0.01% to 5% (w/w) of magnesium stearate
- the present invention relates to process for the preparation of sustained release tablets, wherein the process comprising steps of: (a) sifting and mixing active ingredient, high viscosity polymers, binder and diluent,
- step (d) sifting the glidant using suitable screen and mixing with obtained dried milled granules of step (d) followed by blending and lubricating
- barrier coating is applied over the blend of step (e) followed by film coating and packaging
- the present invention relates to process for preparing sustained release tablet composition Hydroxyzine hydrochloride, wherein the process comprising the steps of:
- step (c) drying the wet granules and milling the dried granules followed by sifting the porous silica using suitable screen and mixing with obtained dried milled granules of step (d) followed by blending and lubricating
- barrier coating is applied over the blend of step (e) over uncoated tablets, followed by film coating and packaging
- the present invention relates to process for the preparation of sustained release tablets, wherein the process comprising steps of:
- step (c) sifting the glidant using suitable screen and mixing with obtained dried milled granules of step (d) followed by blending and lubricating (d) barrier coating is applied over the blend of step (c) followed by film coating and filling the granules of step into capsules or sachets or compressing into minitablets.
- compositions of the present invention when subjected to in vitro changeover dissolution study exhibits following release profile: i) releases not more than 35% in 1 hour, in 900 ml of 0.01N HC1 medium at 50 rpm and 37°C using USP type II apparatus, and ii) releases at least about 40% - 85% in 4 hours and not less than 85% in 10 hours, in 900 ml of pH 6.8 phosphate buffer medium at 50 rpm and 37°C using USP type II apparatus.
- Hydroxyzine as used in the context of the present specification is an active ingredient and relates to the free base form, acid form, salt form, polymorphic crystalline or amorphous form, solvates, ethers, esters, etc. Hydroxyzine is an antihistaminic drug and used for treating allergic skin reactions. It is also used as sedative to treat anxiety and tension.
- Salts include derivatives of an active agent, wherein the active agent is modified by making acid or base addition salts thereof.
- pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid addition salts of basic residues such as amines; alkali or organic addition salts of acidic residues; and the like, or a combination comprising one or more of the foregoing salts.
- the pharmaceutically acceptable salts include salts and the quaternary ammonium salts of the active agent.
- acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; other acceptable inorganic salts include metal salts such as sodium salt, potassium salt, cesium salt, and the like; and alkaline earth metal salts, such as calcium salt, magnesium salt, and the like, or a combination comprising one or more of the foregoing salts.
- inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
- other acceptable inorganic salts include metal salts such as sodium salt, potassium salt, cesium salt, and the like
- alkaline earth metal salts such as calcium salt, magnesium salt, and the like, or a combination comprising one or more of the foregoing salts.
- the present invention relates to sustained release tablet of Hydroxyzine or a pharmaceutically acceptable salt or a solvate thereof to overcome the side effects associated with Hydroxyzine Hydrochloride immediate release tablet.
- the concentration of active ingredient used in the present invention ranges from 20% to 60% (w/w) to the total concentration, most preferably 20 to 28% (w/w).
- pharmaceutically acceptable excipients include, but not limited to, one or more of high viscosity polymers, diluent, glidant, lubricant, water-insoluble release modifier, binder, solvent and the like.
- oral pharmaceutical compositions includes but not limited to all forms of orally administered dosage forms, e.g. a monolithic one, e.g. a tablet or a capsule, or a multiparticulate one, e.g. granules, pellets or microspheres. Multiparticulate compositions may be further processed to form a monolithic dosage form. Preferably, said pharmaceutical composition is in the form of a tablet.
- Suitable “high viscosity polymers” may be selected from polymers having molecular weight of greater than 50,000 daltons.
- High viscosity HPMC polymers include E4M, E10M, K4MCR, K15MCR and KI OOM.
- polymers include copovidone, hypromellose phthalate (hydroxypropylmethylcellulose phthalate, HPMCP), hypromellose acetate succinate (hydroxypropylmethylcellulose acetate succinate, HPMCAS), -2-hydroxypropyl- .beta.-cyclodextrin (HPBCD), povidone, (polyvinyl pyrrolidone, PVP homopolymer), hypromellose (hydroxypropylmethylcellulose, HPMC), polymethacrylates (poly(methacrylic acid, methyl methacrylate 1: 1; poly(methacrylic acid, ethyl acrylate) 1: 1), hydroxypropyl cellulose (HPC), and cellulose acetate phthalate (CAP) and mixtures thereof.
- copovidone hypromellose phthalate
- HPMCP hypromellose acetate succinate
- HPMCAS hydroxypropylmethylcellulose acetate succinate
- HPBCD -2-hydroxyprop
- Preferably used high viscosity polymers are Hypromellose K15MCR, Hypromellose K4MCR or mixtures thereof.
- Less Sedation as used in the context of the present specification is defined as a depressed level of consciousness but the ability to independently and continuously maintain a patient airway and respond appropriately to physical stimulation is retained.
- sustained release as used in the context of the present specification is defined as release of a pharmaceutical agent in a continuous manner over a prolonged period of time.
- Prolonged period of time it is meant a continuous period of time of greater than about 1 hour, preferably, greater than about 4 hours, more preferably, greater than about 8 hours, more preferably greater than about 12 hours, more preferably still, greater than about 16 hours up to more than about 24 hours.
- immediate release refers to immediate release of drug from the compositions after administration. This term is also used by the pharmacopoeias and the FDA. Immediate release dosage forms are designed to give a fast onset of drug action
- rate of release or “release rate” of a drug refers to the quantity of drug released from a dosage form per unit time, e.g., milligrams of drug released per hour (mg/hr) or a percentage of a total drug dose released per hour.
- Drug release rates for dosage forms are typically measured as an in vitro rate of drug release, i.e., a quantity of drug released from the dosage form per unit time measured under appropriate conditions and in a suitable fluid.
- the time at which a specified percentage of the drug within a dosage form has been released from the dosage form is referred to as the “T.sub.x” value, where “x” is the percent of drug that has been released.
- C denotes the concentration of drug in blood plasma, or serum, of a subject, and is generally expressed as mass per unit volume, for example nanograms per milliliter. For convenience, this concentration may be referred to herein as “drug plasma concentration”, “plasma drug concentration” or “plasma concentration” which is intended to be inclusive of a drug concentration measured in any appropriate body fluid or tissue.
- the plasma drug concentration at any time following drug administration is referenced as Ctime, as in C9 hr or C4 hr, etc.
- the maximum plasma drug concentration during the dosing period is referenced as Cmax, while Cmin refers to the minimum blood plasma drug concentration at the end of a dosing interval; and Cave refers to an average concentration during the dosing interval.
- bioavailability refers to an extent to which — and sometimes rate at which — the active moiety (drug or metabolite) enters systemic circulation, thereby gaining access to the site of action.
- AUC is the area under the plasma concentration-time curve and is considered to be the most reliable measure of bioavailability. It is directly proportional to the total amount of unchanged drug that reaches the systemic circulation.
- concentration of high viscosity polymers used in the present invention alone ranges from 1% to 40% (w/w) to the total concentration.
- concentration of high viscosity polymers is from 1.00 to 20% (w/w).
- the Hydroxyzine Hydrochloride SR tablets developed using direct compression method experienced sticking of blend to tablet punch was observed during compression. Even after addition of anti-sticking agent like talc, glyceryl monostearates, calcium stearate, magnesium stearate, stearic acid, glyceryl behenate, and polyethylene glycol, DiCOM DC SR (Coprocessed excipient system for direct compression). Segregation of blend was observed along with punch stickiness during compression.
- anti-sticking agent like talc, glyceryl monostearates, calcium stearate, magnesium stearate, stearic acid, glyceryl behenate, and polyethylene glycol, DiCOM DC SR (Coprocessed excipient system for direct compression). Segregation of blend was observed along with punch stickiness during compression.
- pregelatinized starch were used in the formula composition to improve the manufacturing process.
- a combination of Hydroxypropylmethyl cellulose (HPMCK15MCR and HPMCK4MCR) were used to attain a target dissolution profile.
- the percentage of polymer (A combination of HPMC K15MCR and HPMC K4MCR) at 10 to 30% w/w, preferably 12%, Preferably 15%, preferably 17.5%, preferably 20%, preferably 25%, preferably 30% w/w of core tablet, followed by barrier coating with Ethyl cellulose and HPC in a ratio of 65:35 at a weight gain of 3% w/w over core tablets was found to be an ideal composition to control the drug release profile. More preferably polymer at 17.5%, w/w of core tablet is found to be more suitable.
- Suitable diluent may be selected from, but not limited to the group consisting of microcrystalline cellulose, lactose monohydrate, sucrose, fructose, glucose dextrose, or other sugars, dibasic calcium phosphate, calcium sulfate, cellulose, ethylcellulose, cellulose derivatives, kaolin, mannitol, lactitol, maltitol, xylitol, sorbitol, or other sugar alcohols, dry starch, saccharides, dextrin, maltodextrin or other polysaccharides, inositol or mixtures thereof.
- Preferably used diluent is Lactose monohydrate.
- concentration of diluent used in the present invention ranges from 20% to 70% (w/w) to the total concentration, most preferably 35 to 55 % (w/w).
- Suitable binder may be selected from, but not limited to the group consisting of polyvinylpyrrolidone (PVP), copovidone, hydroxypropyl cellulose (Klucel EXF), hydroxypropylmethyl cellulose, hydroxyethyl cellulose, methylcellulose, and combinations thereof.
- PVP polyvinylpyrrolidone
- copovidone hydroxypropyl cellulose
- hydroxypropyl cellulose hydroxyethyl cellulose
- methylcellulose methylcellulose
- Preferably used binder is Hydroxypropyl cellulose.
- the concentration of binder used in the present invention ranges from 0.05% to 10% (w/w) to the total concentration, most preferably 1 to 4.5% (w/w).
- Suitable glidant may be selected from, but not limited to the group consisting of porous silica, colloidal silicon dioxide, cellulose, calcium phosphate, di or tri-basic and the like. Preferably used glidant is porous silica.
- the concentration of glidant used in the present invention ranges from 0.05% to 5% (w/w) to the total concentration, most preferably 1 to 3% (w/w).
- Suitable lubricant includes, for example, magnesium stearate, stearic acid, sodium stearyl fumarate, sodium lauryl sulfate, glyceryl palmitostearate, and any combination thereof.
- magnesium stearate Preferably used lubricant magnesium stearate.
- the concentration of lubricant used in the present invention ranges from 0.01% to 5% (w/w) to the total concentration, most preferably 0.05 to 5% (w/w).
- Suitable water-insoluble release modifier may be selected from, but not limited to the group consisting of polyvinyl acetate, polyvinyl chloride, polyvinyl carbonate, ethyl cellulose, nitrocellulose, vinylidene chloride-acrylonitrile copolymer, acrylonitrile-styrene copolymer, ethylene vinyl acetate, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, copolymers of vinyl pyrrolidone, blend of polymers comprising polyvinyl acetate, hydroxypropylmethylcellulose phthalate, methacrylic acid copolymers such as Eudragit® LI00/SI00/LI00-55 and the like or mixtures thereof; methacrylate copolymers such as Eudragit® E100/EPO, Eudragit® RL100/RL30D/RLPO, Eudragit® RS100/RS30D/RSPO and the like or mixtures thereof.
- the concentration of water-insoluble release modifier used in barrier of present invention ranges from 0.05% to 10% to the total concentration, most preferably 1 to 5% (w/w).
- Pore forming agent hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, glycerol, propylene glycol, polyethylene glycol, sucrose, mannitol, lactose, sodium chloride or a combination thereof.
- Preferably used pore forming agent is Hydroxypropyl cellulose.
- the concentration of pore forming agent used in the present invention ranges from 0.05% to 10% (w/w) to the total concentration, most preferably 1 to 5% (w/w)
- Film coating used in the present invention is preferably opadry film coating, hydroxypropyl cellulose, hypromellose, eudragit coating agents, most preferably Opadry AMB II white and Opadry AMB.
- the concentration of opadry film coating used in the present invention ranges from 0.1 % to 5% (w/w) to the total concentration, most preferably 2 to 5% (w/w).
- the pharmaceutical composition of the present specification is stable throughout the shelf life when the compositions is subjected to accelerated and long-term stability studies.
- compositions prepared as per example le were evaluated through accelerated stability studies.
- the composition prepared according to the formula and process of example le was subjected to stability study at 30°C/75% RH and 40 °C/75% RH.
- the compositions were found to be stable at accelerated conditions.
- Table 1 and Table 2 represents the study result data.
- Table 1 Stability Data of Hydroxyzine hydrochloride sustained release tablet of the present invention according to Example 1 (Storage Condition: 30°C/75% RH)
- Table 2 Stability Data of Hydroxyzine hydrochloride sustained release tablet of the present invention according to Example 1 (Storage Condition: 40°C/75% RH)
- Comparative Bioequivalence Study with Blunt Cmax A Randomized, Open Label, Balanced, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Comparative Bioavailability Study of Hydroxyzine Sustained Release Tablet of the present invention., Comparing with two tablets of Atarax® 25 mg Dr. Reddy’s Laboratories Limited, in Normal Healthy Adult Human Subjects Under Easting Conditions.
- the 90% confidence intervals of geometric least square mean ratio of In-transformed pharmacokinetic parameters AUCO-t and AUCO-inf between test and reference products falls within the range of 80.00% to 125.00% for Hydroxyzine. Therefore, the compositions of the present invention were found to be efficacious with less sedative effect i.e the test formulation is having blunt Cmax compared to the reference.
- compositions of the present invention were based on a medical review of adverse events (AEs), physical examination, recording of vital signs and clinical laboratory tests.
- AEs adverse events
- the compositions of the Example 1 were well tolerated and was found to be safe.
- test SR formulation has shown steady and consistent increase in concentration vowing to lesser adverse effects like sedation and also the test SR formulation Cmax was steadily increasing in ascending order and the maximum concentration is observed at 6.0 hr but in reference IR formulation the maximum concentration was observed at 2.5 hrs post dose which shows that the formulation of present invention has benefit of avoiding sedation as side effect.
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to sustained release composition of Hydroxyzine or a pharmaceutically acceptable salt or a solvate thereof with less sedation. The present invention also relates sustained release compositions of Hydroxyzine hydrochloride comprising core matrix, barrier coating and film coating. The invention also relates to method of preparation of such compositions of Hydroxyzine or pharmaceutically acceptable salts or solvate thereof.
Description
SUSTAINED RELEASE COMPOSITION OF HYDROXYZINE AND IT’S PROCESS
CROSS REFERENCE
This application claims priority from Indian Patent Application No. 202241064146 filed on November 10, 2022.
TECHNICAL FIELD OF THE INVENTION
The present invention relates to sustained release compositions of Hydroxyzine or a pharmaceutically acceptable salt or a solvate thereof. The present invention also relates to sustained release compositions of Hydroxyzine hydrochloride comprising core matrix, barrier coating and film coating with less sedation. The invention also relates to a method of preparation of such compositions of Hydroxyzine or pharmaceutically acceptable salts or solvate thereof.
BACKGROUND OF THE INVENTION
Hydroxyzine (hye drox' i zeen) is a first generation antihistamine that is used mostly to treat itching and nausea. Because of its sedating effects, hydroxyzine is also used for anxiety, tension and as a mild sleeping aid. Hydroxyzine belongs to the piperazine class of antihistamines (with cyclizine and meclizine) which are more commonly used for itching, nausea and anxiety than for their effects on symptoms of allergic rhinitis or coryza. Hydroxyzine was approved for use in the United States in 1956 and continues to be widely used. It is available as tablet and capsule dosage forms of 10, 25, 50 and 100 mg under the trade names Atarax and Vistaril. Hydroxyzine hydrochloride is chemically known as l-(p- chlorobenzhydryl) 4-[2-(2-hydroxyethoxy)-ethyl] piperazine dihydrochloride with the chemical formula C21H27CIN2O2 • 2HC1, molecular weight of 447.83 g/mol and has the following chemical structure:
U.S. Patent No. 2,899,436 A discloses Hydroxyzine product generically.
U.S. Patent No. 3,577,514A discloses sustained release pharmaceutical tablet composition of Hydroxyzine characterized by a substantially constant rate of drug release comprising; (a) medicament; (b) a hydrophobic dissolution retardant; (c) an acid-insoluble release agent; and (d) a water-soluble or dispersible binder.
WO 2001/051033 Al discloses solid pharmaceutical composition for oral administration, allowing controlled release by at least one active substance, consisting of a homogeneous mixture including: a) said at least one substance; b) between 5 and 95% by weight, relative to the total weight of the composition, of at least one matrix excipient; c) between 2 and 50% by weight, relative to the total weight of the composition, of at least one enteric-soluble polymer; and d) between 0.5 and 50% by weight, relative to the total weight of the composition, of at least an alkalizing agent soluble in an aqueous phase under pH conditions physiological. This publication discloses Hydroxyzine as a substance in a laundry list.
U.S. Publication No. 2021/0228488 Al discloses an extended release pharmaceutical composition comprising plurality of modified release units wherein each unit comprises of an active agent core comprising at least one pharmaceutically active agent and at least one pharmaceutically acceptable excipient, substantially coated with at least one releasecontrolling agent. Hydroxyzine is disclosed as active agent.
Ghosh et al., Asian Journal of Pharmaceutics, 2014, 230-236 discloses hydroxyzine hydrochloride sustained release microspheres by ionotropic gelation technique using Carbopol 934P.
The prior arts described above discloses sustained release pharmaceutical compositions comprising medicament (Hydroxyzine), hydrophobic dissolution retardant, an acid-insoluble
release agent, a water-soluble or dispersible binder, controller release formulation comprising substance, matrix excipient, enteric-soluble polymer, alkalizing agent, extended release pharmaceutical composition comprising plurality of modified release units, hydroxyzine hydrochloride sustained release microspheres. But none of the prior arts are feasible at higher manufacturing capacities. Further, sedation and drowsiness are the major side effects observed with available immediate release formulations of Hydroxyzine Hydrochloride available in market.
To overcome these side effects and manufacturing problems, inventors of the present invention have developed sustained release oral composition of Hydroxyzine or its pharmaceutically acceptable salt. Further, the inventors of the present invention provide sustained release tablet composition of Hydroxyzine hydrochloride which is targeted to release the drug with blunted Cmax with plasma concentration values ranging between 40±12 ng/mL, thus the formulation of the present invention has a potential to reduce the exposure to high levels of the drug, while maintaining the efficacy. The inventors of the present invention also provide method of preparation of sustained release tablet composition of Hydroxyzine or its pharmaceutically acceptable salts using wet granulation and direct compression.
OBJECT OF THE INVENTION
The main aspect of the present invention is to provide sustained release oral pharmaceutical compositions of Hydroxyzine or its pharmaceutically acceptable salt or a solvate thereof with less sedative effect.
In another aspect, the present invention relates to sustained release oral pharmaceutical compositions comprising Hydroxyzine or its pharmaceutically acceptable salts as active ingredient along with other pharmaceutically acceptable excipients.
In yet another aspect, the present invention relates to the oral pharmaceutical compositions of the present invention include tablets, capsules, mini-tablets, granules.
In another aspect, the present invention relates to sustained release tablet composition of Hydroxyzine or its pharmaceutically acceptable salt comprising a) core matrix, b) barrier coating and c) film coating.
In yet another aspect, the present invention relates to sustained release tablet composition comprising Hydroxyzine or its pharmaceutically acceptable salt, high viscosity polymers, diluents, binder, filler, glidant, water-insoluble release modifier, pore forming agent, lubricant, solvents as pharmaceutically acceptable excipients.
In still another aspect, the present invention relates to sustained release tablet composition of Hydroxyzine or its pharmaceutically acceptable salt comprising a) core matrix containing active ingredient, high viscosity polymers, diluent, binder, glidant, lubricant, solvents, b) barrier coating containing water-insoluble release modifier, pore forming agent, solvents and c) film coating containing opadry film coating and solvent.
In yet another aspect of the present invention relates to process for the preparation of sustained release tablet composition of Hydroxyzine or its pharmaceutically acceptable salt comprising the steps of sifting, wet granulation, drying, milling, blending, lubrication, direct compression, barrier coating, film coating and packing.
In yet another aspect of the present invention provides a sustained release composition of Hydroxyzine or its pharmaceutically acceptable salt which is targeted to release the drug with blunted Cmax with plasma concentration values ranging between 40±12 ng/mL, thus has a potential to reduce the exposure to high levels of the molecule, while still maintaining efficacy.
In yet another aspect, the compositions of the present invention when subjected to in vitro changeover dissolution study exhibits following release profile: i) releases not more than 35% in 1 hour, in 900 ml of 0.01N HC1 medium at 50 rpm and 37°C using USP type II apparatus, and ii) releases at least about 40% - 85% in 4 hours and not less than 85% in 10 hours, in 900 ml of pH 6.8 phosphate buffer medium at 50 rpm and 37°C using USP type II apparatus.
SUMMARY OF THE INVENTION
Accordingly, the present invention relates to sustained release tablet of Hydroxyzine or a pharmaceutically acceptable salt or a solvate thereof to overcome the side effects associated with Hydroxyzine Hydrochloride immediate release tablet.
In another aspect, the present invention relates to sustained release oral pharmaceutical compositions comprising Hydroxyzine or its pharmaceutically acceptable salts as active ingredient along with other pharmaceutically acceptable excipients.
In yet another aspect, the present invention relates to the oral pharmaceutical compositions of the present invention include tablets, capsules, mini-tablets, granules.
In another aspect, the present invention relates to sustained release tablet composition comprising Hydroxyzine or a pharmaceutically acceptable salt as active ingredient and pharmaceutically acceptable excipients.
In yet another aspect, the present invention relates to sustained release tablet composition comprising Hydroxyzine or a pharmaceutically acceptable salt as active ingredient, high viscosity polymers, diluents, binder, filler, glidant, water-insoluble release modifier, pore forming agent, lubricant, solvents as pharmaceutically acceptable excipients.
In still another aspect, the present invention relates to sustained release tablet composition comprising a) core matrix, b) barrier coating and c) film coating.
In another aspect, the present invention relates to sustained release tablet composition of Hydroxyzine or a pharmaceutically acceptable salt comprising a) core matrix comprising active ingredient, high viscosity polymers, diluent, binder, glidant, lubricant, solvents, b) barrier coating comprising water-insoluble release modifier, pore forming agent, solvents and c) film coating comprising opadry film coating and solvent.
In yet another aspect, the present invention relates to sustained release tablet composition of Hydroxyzine or a pharmaceutically acceptable salt comprising a) core matrix comprising
Hydroxyzine or a pharmaceutically acceptable salt as active ingredient, Hypromellose K15MCR, Hypromellose K4MCR, Hypromellose E4M, Hypromellose E10M as high viscosity polymers, Lactose monohydrate, mannitol, dibasic calcium phosphate as diluent, Hydroxypropyl cellulose (Kluel EXF), polyvinylpyrrolidone (PVP), copovidone as binder, porous silica (Syloid® 244 FP silica), colloidal silicon dioxide, cellulose as glidant, magnesium stearate, sodium stearyl fumarate, sodium lauryl sulfate as lubricant, isopropyl alcohol, purified water as solvents, b) barrier coating containing ethyl cellulose, polyvinyl acetate, polyvinyl chloride as water-insoluble release modifier, Hydroxypropyl cellulose (Kluel EF), glycerol, propylene glycol as pore forming agent, isopropyl alcohol, acetone as solvents and c) film coating containing Opadry AMB white as opadry film coating which comprises polyvinyl alcohol-part hydrolyzed, titanium dioxide, talc, lecithin and polyvinyl alcohol-part hydrolyzed, purified water as solvent or Opadry AMB II which comprises Polyvinyl alcohol, Talc, Titanium dioxide, GMCC Type-1 and sodium lauryl sulfate.
Another aspect of the present invention relates to provide process for the preparation of oral sustained release pharmaceutical compositions of Hydroxyzine or its pharmaceutically acceptable salts.
Another aspect of the present invention relates to provide process for the preparation of sustained release tablet composition of Hydroxyzine hydrochloride comprising the steps of dispensing, sifting, wet granulation, drying, milling, blending, lubrication, direct compression, barrier coating, film coating and packing.
In another aspect, the present invention relates to sustained release tablet composition comprising: a) core matrix:
20% to 60% (w/w) of active ingredient, 1% to 40% (w/w) of high viscosity polymers, 20% to 70% (w/w) of diluent, 0.05% to 10% (w/w) of binder, 0.05% to 5% (w/w) of glidant,
0.01% to 5% (w/w) of lubricant, and
QS of solvents. b) barrier coating:
0.05% to 10% (w/w) of water-insoluble release modifier,
0.05% to 10% (w/w) of pore forming agent, and
QS of solvents, and/or c) film coating:
0.1% to 5% (w/w) of opadry film coating, and QS of solvent.
In yet another aspect, the present invention relates to sustained release tablet composition Hydroxyzine hydrochloride comprising: a) core matrix:
20% to 60% (w/w) of Hydroxyzine hydrochloride,
1 % to 40% (w/w) of Hypromellose,
20% to 70% (w/w) of lactose monohydrate,
0.1% to 10% (w/w) of Hydroxypropyl cellulose,
0.05% to 5% (w/w) of porous silica,
0.01% to 5% (w/w) of magnesium stearate, and
QS of isopropyl alcohol and purified water. b) barrier coating:
0.05% to 10% (w/w) of ethyl cellulose,
0.05% to 10% (w/w) of hydroxypropyl cellulose,
QS of isopropyl alcohol and acetone, and/or c) film coating:
0.1% to 5% (w/w) of Opadry, and
QS of purified water.
In yet another aspect, the present invention relates to process for the preparation of sustained release tablets, wherein the process comprising steps of:
(a) sifting and mixing active ingredient, high viscosity polymers, binder and diluent,
(b) transferring co-sifted material into rapid mixer granulator (RMG), dry mixing and adding the mixture of solvents ,
(c) drying the wet granules in Fluid bed processor, milling the dried granules
(d) sifting the glidant using suitable screen and mixing with obtained dried milled granules of step (d) followed by blending and lubricating
(e) compressing the lubricated blend using suitable punch toolings in compression machine,
(f) barrier coating is applied over the blend of step (e) followed by film coating and packaging
In yet another aspect, the present invention relates to process for preparing sustained release tablet composition Hydroxyzine hydrochloride, wherein the process comprising the steps of:
(a) sifting and mixing Hydroxyzine hydrochloride, Hypromellose, Hydroxypropyl cellulose and lactose monohydrate,
(b) transferring co-sifted material into rapid mixer granulator (RMG), dry mixing
(c) drying the wet granules and milling the dried granules followed by sifting the porous silica using suitable screen and mixing with obtained dried milled granules of step (d) followed by blending and lubricating
(d) compressing the lubricated blend using suitable punch toolings in compression machine,
(e) barrier coating is applied over the blend of step (e) over uncoated tablets, followed by film coating and packaging
In yet another aspect, the present invention relates to process for the preparation of sustained release tablets, wherein the process comprising steps of:
(a) sifting and mixing active ingredient, high viscosity polymers, binder and diluent,
(b) transferring co-sifted material into rapid mixer granulator (RMG), followed by dry mixing and milling
(c) sifting the glidant using suitable screen and mixing with obtained dried milled granules of step (d) followed by blending and lubricating
(d) barrier coating is applied over the blend of step (c) followed by film coating and filling the granules of step into capsules or sachets or compressing into minitablets.
In yet another aspect, the compositions of the present invention when subjected to in vitro changeover dissolution study exhibits following release profile: i) releases not more than 35% in 1 hour, in 900 ml of 0.01N HC1 medium at 50 rpm and 37°C using USP type II apparatus, and ii) releases at least about 40% - 85% in 4 hours and not less than 85% in 10 hours, in 900 ml of pH 6.8 phosphate buffer medium at 50 rpm and 37°C using USP type II apparatus.
DESCRIPTION OF INVENTION
The term "comprising", which is synonymous with "including", "containing", or "characterized by" here is defined as being inclusive or open-ended, and does not exclude additional, unrecited elements or method steps, unless the context clearly requires otherwise.
The term “Hydroxyzine” as used in the context of the present specification is an active ingredient and relates to the free base form, acid form, salt form, polymorphic crystalline or amorphous form, solvates, ethers, esters, etc. Hydroxyzine is an antihistaminic drug and used for treating allergic skin reactions. It is also used as sedative to treat anxiety and tension.
"Salts" include derivatives of an active agent, wherein the active agent is modified by making acid or base addition salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid addition salts of basic residues such as amines; alkali or organic addition salts of acidic residues; and the like, or a combination comprising one or more of the foregoing salts. The pharmaceutically acceptable salts include salts and the quaternary ammonium salts of the active agent. For example, acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; other acceptable inorganic salts include metal salts such as sodium salt, potassium salt, cesium salt, and the like; and alkaline earth metal salts, such as
calcium salt, magnesium salt, and the like, or a combination comprising one or more of the foregoing salts.
In still another aspect, the present invention relates to sustained release tablet of Hydroxyzine or a pharmaceutically acceptable salt or a solvate thereof to overcome the side effects associated with Hydroxyzine Hydrochloride immediate release tablet.
The concentration of active ingredient used in the present invention ranges from 20% to 60% (w/w) to the total concentration, most preferably 20 to 28% (w/w).
The term “pharmaceutically acceptable excipients” include, but not limited to, one or more of high viscosity polymers, diluent, glidant, lubricant, water-insoluble release modifier, binder, solvent and the like.
The term “oral pharmaceutical compositions” as used herein includes but not limited to all forms of orally administered dosage forms, e.g. a monolithic one, e.g. a tablet or a capsule, or a multiparticulate one, e.g. granules, pellets or microspheres. Multiparticulate compositions may be further processed to form a monolithic dosage form. Preferably, said pharmaceutical composition is in the form of a tablet.
Suitable “high viscosity polymers” may be selected from polymers having molecular weight of greater than 50,000 daltons. High viscosity HPMC polymers include E4M, E10M, K4MCR, K15MCR and KI OOM. Other polymers include copovidone, hypromellose phthalate (hydroxypropylmethylcellulose phthalate, HPMCP), hypromellose acetate succinate (hydroxypropylmethylcellulose acetate succinate, HPMCAS), -2-hydroxypropyl- .beta.-cyclodextrin (HPBCD), povidone, (polyvinyl pyrrolidone, PVP homopolymer), hypromellose (hydroxypropylmethylcellulose, HPMC), polymethacrylates (poly(methacrylic acid, methyl methacrylate 1: 1; poly(methacrylic acid, ethyl acrylate) 1: 1), hydroxypropyl cellulose (HPC), and cellulose acetate phthalate (CAP) and mixtures thereof. Preferably used high viscosity polymers are Hypromellose K15MCR, Hypromellose K4MCR or mixtures thereof.
The term “Less Sedation” as used in the context of the present specification is defined as a depressed level of consciousness but the ability to independently and continuously maintain a patient airway and respond appropriately to physical stimulation is retained.
The term “Sustained release” as used in the context of the present specification is defined as release of a pharmaceutical agent in a continuous manner over a prolonged period of time.
By “prolonged period of time” it is meant a continuous period of time of greater than about 1 hour, preferably, greater than about 4 hours, more preferably, greater than about 8 hours, more preferably greater than about 12 hours, more preferably still, greater than about 16 hours up to more than about 24 hours.
The term “immediate release” as used herein refers to immediate release of drug from the compositions after administration. This term is also used by the pharmacopoeias and the FDA. Immediate release dosage forms are designed to give a fast onset of drug action
As used herein, unless otherwise noted, “rate of release” or “release rate” of a drug refers to the quantity of drug released from a dosage form per unit time, e.g., milligrams of drug released per hour (mg/hr) or a percentage of a total drug dose released per hour. Drug release rates for dosage forms are typically measured as an in vitro rate of drug release, i.e., a quantity of drug released from the dosage form per unit time measured under appropriate conditions and in a suitable fluid. The time at which a specified percentage of the drug within a dosage form has been released from the dosage form is referred to as the “T.sub.x” value, where “x” is the percent of drug that has been released.
“C” denotes the concentration of drug in blood plasma, or serum, of a subject, and is generally expressed as mass per unit volume, for example nanograms per milliliter. For convenience, this concentration may be referred to herein as “drug plasma concentration”, “plasma drug concentration” or “plasma concentration” which is intended to be inclusive of a drug concentration measured in any appropriate body fluid or tissue. The plasma drug concentration at any time following drug administration is referenced as Ctime, as in C9 hr or C4 hr, etc.
The maximum plasma drug concentration during the dosing period is referenced as Cmax, while Cmin refers to the minimum blood plasma drug concentration at the end of a dosing interval; and Cave refers to an average concentration during the dosing interval.
The term “bioavailability” refers to an extent to which — and sometimes rate at which — the active moiety (drug or metabolite) enters systemic circulation, thereby gaining access to the site of action.
“AUC” is the area under the plasma concentration-time curve and is considered to be the most reliable measure of bioavailability. It is directly proportional to the total amount of unchanged drug that reaches the systemic circulation.
The concentration of high viscosity polymers used in the present invention alone ranges from 1% to 40% (w/w) to the total concentration. Preferably used concentration of high viscosity polymers is from 1.00 to 20% (w/w).
The Hydroxyzine Hydrochloride SR tablets developed using direct compression method experienced sticking of blend to tablet punch was observed during compression. Even after addition of anti-sticking agent like talc, glyceryl monostearates, calcium stearate, magnesium stearate, stearic acid, glyceryl behenate, and polyethylene glycol, DiCOM DC SR (Coprocessed excipient system for direct compression). Segregation of blend was observed along with punch stickiness during compression.
Further to avoid the problem of punch sticking different excipients were tried like spray dried lactose/ Anhydrous Lactose, pregelatinized starch were used in the formula composition to improve the manufacturing process. A combination of Hydroxypropylmethyl cellulose (HPMCK15MCR and HPMCK4MCR) were used to attain a target dissolution profile.
With intent of generating a stable sustained release formulation, two dissolution profiles with 12 hr and 16hr dissolution profiles were targeted to achieve the desired target. Polymer quantities were used at a ratio of 15 to 30% w/w, preferably 17.5%w/w and 25%w/w in core tablet formulations. Hydroxypropyl cellulose is used as a binder for granulation. The dried granules were mixed with colloidal silica and Magnesium stearate and compressed. The core
tablets were coated with a barrier coating (Ethyl cellulose and Hydroxypropyl cellulose combination) in coating machine followed by film coating using Opadry AMB white.
Formula with higher polymer quantity and with High viscous polymer (HPMCK15MCR), the desired dissolution profile completed in 16hr.
On the basis of development trials, the percentage of polymer (A combination of HPMC K15MCR and HPMC K4MCR) at 10 to 30% w/w, preferably 12%, Preferably 15%, preferably 17.5%, preferably 20%, preferably 25%, preferably 30% w/w of core tablet, followed by barrier coating with Ethyl cellulose and HPC in a ratio of 65:35 at a weight gain of 3% w/w over core tablets was found to be an ideal composition to control the drug release profile. More preferably polymer at 17.5%, w/w of core tablet is found to be more suitable.
Suitable diluent, may be selected from, but not limited to the group consisting of microcrystalline cellulose, lactose monohydrate, sucrose, fructose, glucose dextrose, or other sugars, dibasic calcium phosphate, calcium sulfate, cellulose, ethylcellulose, cellulose derivatives, kaolin, mannitol, lactitol, maltitol, xylitol, sorbitol, or other sugar alcohols, dry starch, saccharides, dextrin, maltodextrin or other polysaccharides, inositol or mixtures thereof. Preferably used diluent is Lactose monohydrate.
The concentration of diluent used in the present invention ranges from 20% to 70% (w/w) to the total concentration, most preferably 35 to 55 % (w/w).
Suitable binder may be selected from, but not limited to the group consisting of polyvinylpyrrolidone (PVP), copovidone, hydroxypropyl cellulose (Klucel EXF), hydroxypropylmethyl cellulose, hydroxyethyl cellulose, methylcellulose, and combinations thereof. Preferably used binder is Hydroxypropyl cellulose.
The concentration of binder used in the present invention ranges from 0.05% to 10% (w/w) to the total concentration, most preferably 1 to 4.5% (w/w).
Suitable glidant, may be selected from, but not limited to the group consisting of porous silica, colloidal silicon dioxide, cellulose, calcium phosphate, di or tri-basic and the like. Preferably used glidant is porous silica.
The concentration of glidant used in the present invention ranges from 0.05% to 5% (w/w) to the total concentration, most preferably 1 to 3% (w/w).
Suitable lubricant includes, for example, magnesium stearate, stearic acid, sodium stearyl fumarate, sodium lauryl sulfate, glyceryl palmitostearate, and any combination thereof. Preferably used lubricant magnesium stearate.
The concentration of lubricant used in the present invention ranges from 0.01% to 5% (w/w) to the total concentration, most preferably 0.05 to 5% (w/w).
Suitable water-insoluble release modifier may be selected from, but not limited to the group consisting of polyvinyl acetate, polyvinyl chloride, polyvinyl carbonate, ethyl cellulose, nitrocellulose, vinylidene chloride-acrylonitrile copolymer, acrylonitrile-styrene copolymer, ethylene vinyl acetate, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, copolymers of vinyl pyrrolidone, blend of polymers comprising polyvinyl acetate, hydroxypropylmethylcellulose phthalate, methacrylic acid copolymers such as Eudragit® LI00/SI00/LI00-55 and the like or mixtures thereof; methacrylate copolymers such as Eudragit® E100/EPO, Eudragit® RL100/RL30D/RLPO, Eudragit® RS100/RS30D/RSPO and the like or mixtures thereof. Preferably used water-insoluble release modifier is ethyl cellulose.
The concentration of water-insoluble release modifier used in barrier of present invention ranges from 0.05% to 10% to the total concentration, most preferably 1 to 5% (w/w).
Pore forming agent hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, glycerol, propylene glycol, polyethylene glycol, sucrose, mannitol, lactose, sodium chloride or a combination thereof. Preferably used pore forming agent is Hydroxypropyl cellulose.
The concentration of pore forming agent used in the present invention ranges from 0.05% to 10% (w/w) to the total concentration, most preferably 1 to 5% (w/w)
Film coating used in the present invention is preferably opadry film coating, hydroxypropyl cellulose, hypromellose, eudragit coating agents, most preferably Opadry AMB II white and Opadry AMB.
The concentration of opadry film coating used in the present invention ranges from 0.1 % to 5% (w/w) to the total concentration, most preferably 2 to 5% (w/w).
During stability of samples, immediate dissolution was observed. In order to address the issue of fastness in dissolution profile during stability, trials were executed with binder(s) (to create a binding force between the particles), water insoluble diluents like microcrystalline cellulose, pregelatinized starch (which acts as binder and gives additional strength to tablets) and by increasing the polymer content in formulation. Inspite of all these trials to match the target dissolution profile, during stability, the dissolution profile became faster in all trial batches. In order to make a stable formulation, wet granulation was opted to make stronger granules, followed by barrier coating with ethyl cellulose and film coating with Opadry AMB white.
The pharmaceutical composition of the present specification is stable throughout the shelf life when the compositions is subjected to accelerated and long-term stability studies.
The following examples will further describe certain specific aspects and embodiments of the invention in greater details and are not intended to limit the scope of invention
EXAMPLES
Process for preparing Tablets: a. Hydroxyzine hydrochloride, hypromellose, Lactose monohydrate and hydroxypropyl cellulose were mixed as per the quantities given in Example 1. b. Co-sifted the mixture and was transferred into rapid mixer granulator (RMG), obtain suitable dried granules, isopropyl alcohol and purified water mixture was added and were dried in Fluid bed processor c. The dried granules were milled and Porous silica mixed and blended d. Magnesium stearate was added and compressed using suitable punch toolings in compression machine. e. The blend of step d was coated with barrier coating and finally film coated.
Stability Study:
The stability of the compositions prepared as per example le was evaluated through accelerated stability studies. The composition prepared according to the formula and process of example le was subjected to stability study at 30°C/75% RH and 40 °C/75% RH. The compositions were found to be stable at accelerated conditions. Table 1 and Table 2 represents the study result data.
Table 1: Stability Data of Hydroxyzine hydrochloride sustained release tablet of the present invention according to Example 1 (Storage Condition: 30°C/75% RH)
Table 2: Stability Data of Hydroxyzine hydrochloride sustained release tablet of the present invention according to Example 1 (Storage Condition: 40°C/75% RH)
From the above comparison formulation according to Example le at storage conditions 30°C/75% RH and 40°C/75% RH are complied with the specification limits.
Comparative Bioequivalence Study with Blunt Cmax: A Randomized, Open Label, Balanced, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Comparative Bioavailability Study of Hydroxyzine Sustained Release Tablet of the present invention., Comparing with two tablets of Atarax® 25 mg Dr. Reddy’s Laboratories Limited, in Normal Healthy Adult Human Subjects Under Easting Conditions.
The Ratio, 90% confidence intervals and intra subject variability of In-transformed pharmacokinetic parameters are summarized below:
Efficacy Results:
The 90% confidence intervals of geometric least square mean ratio of In-transformed pharmacokinetic parameters AUCO-t and AUCO-inf between test and reference products falls within the range of 80.00% to 125.00% for Hydroxyzine. Therefore, the compositions of the present invention were found to be efficacious with less sedative effect i.e the test formulation is having blunt Cmax compared to the reference.
Safety Results:
Safety assessments of the compositions of the present invention were based on a medical review of adverse events (AEs), physical examination, recording of vital signs and clinical laboratory tests. The compositions of the Example 1 were well tolerated and was found to be safe.
Table 5: Mean Concentration of test (T) and reference (R) products for Hydroxyzine under fasting condition:
From the above results, it clearly states that Onset on action of both test SR formulation and reference IR formulation were similar, however the test SR formulation has shown steady and consistent increase in concentration vowing to lesser adverse effects like sedation and also the test SR formulation Cmax was steadily increasing in ascending order and the maximum concentration is observed at 6.0 hr but in reference IR formulation the maximum concentration was observed at 2.5 hrs post dose which shows that the formulation of present invention has benefit of avoiding sedation as side effect.
From above results of Table 6 it was found that only ~7% subjects treated with experienced sedation compared to the -77% subjects when treated with reference formulation, which shows that the test formulation is less sedative compared to reference formulation by almost lOtimes.
Claims
1. An oral pharmaceutical composition comprising Hydroxyzine, or its pharmaceutically acceptable salts as active ingredient along with other pharmaceutically acceptable excipients, with less sedation, wherein the pharmaceutically acceptable excipients are selected from high viscosity polymers, diluents, binder, filler, glidant, water-insoluble release modifier, pore forming agent, lubricant, solvents
2. The composition as claimed in claim 1, wherein the composition is tablets, capsules, minitablets, granules.
3. The composition as claimed in claim 1, wherein the composition is a sustained release dosage form comprising Hydroxyzine, or a pharmaceutically acceptable salt as active ingredient and pharmaceutically acceptable excipients.
4. A sustained release oral dosage form of hydroxyzine, or its pharmaceutically acceptable salts, comprising a) core matrix, b) a barrier coating surrounding the core and c) an outer film coating.
5. The sustained release oral dosage form as claimed in claim 5, wherein the dosage form comprises a) a core matrix comprising the active ingredient and one or more high viscosity polymers; b) a barrier coating comprising atleast one water-insoluble release modifier and a pore forming agent; and c)a film coating.
6. The sustained release oral dosage form as claimed in claim 5, wherein Hydroxyzine, or its pharmaceutically active salt comprise 20% to 60% (w/w) of the core matrix.
7. The sustained release oral dosage form as claimed in claim 6, wherein one or more high viscosity polymers in the core matrix is selected from the group consisting of HPMC polymers, copovidone, hypromellose phthalate, hypromellose acetate succinate, -2- hydroxypropyl-. beta. -cyclodextrin (HPBCD), povidone, polymethacrylates, hydroxypropyl cellulose (HPC), and cellulose acetate phthalate (CAP) and mixtures thereof.
8. The sustained release oral dosage form as claimed in claim 6, wherein barrier coating comprises ethyl cellulose, polyvinyl acetate, polyvinyl chloride as water-insoluble release modifier, Hydroxypropyl cellulose, glycerol, propylene glycol or mixture thereof as pore forming agent
9. The sustained release oral dosage form as claimed in claim 6, is targeted to release the drug with blunted Cmax with plasma concentration values ranging between 40±12 ng/mL, and has low sedative effect.
10. A method of preparing of composition of claim 5, where in the method comprises:
(a) sifting and mixing hydroxyzine with pharmaceutically active ingredients,
(b) dry mixing the granules of step (a) and adding the mixture of solvents
(c) drying the wet granules, milling and sifting followed by blending and lubricating with lubricant
(f) compressing the lubricated blend followed by barrier coating and film coating
11. The composition of claim 5, wherein composition when subjected to in vitro changeover dissolution study exhibits following release profile: i) releases not more than 35% in 1 hour, ii) releases at least about 40% - 85% in 4 hours and not less than 85% in 10 hours, in 900 ml of pH 6.8 phosphate buffer medium at 50 rpm and 37°C using USP type II apparatus.
12. The sustained release oral dosage form as claimed in claim 5, wherein the dosage form is a tablet capsule, mini-tablet, or granules.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202241064146 | 2022-11-10 | ||
IN202241064146 | 2022-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024100682A1 true WO2024100682A1 (en) | 2024-05-16 |
Family
ID=91032270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2023/051037 WO2024100682A1 (en) | 2022-11-10 | 2023-11-09 | Sustained release composition of hydroxyzine and it's process |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024100682A1 (en) |
-
2023
- 2023-11-09 WO PCT/IN2023/051037 patent/WO2024100682A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4999466B2 (en) | Matrix-type sustained-release preparation containing basic drug or salt thereof and method for producing the same | |
US6515010B1 (en) | Carvedilol methanesulfonate | |
US20230381194A1 (en) | Suspension for oral administration comprising amorphous tolvaptan | |
US20110218216A1 (en) | Extended release pharmaceutical composition of donepezil | |
DK2588086T3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING 4-AMINO-5-FLUORO-3- [6- (4-METHYLPIPERAZIN-1-YL) -1H-BENZIMIDAZOL-2-YL] -1H-QUINOLIN-2-ON-LACTATE MONOHYDRATE | |
US20080292695A1 (en) | Carvedilol forms, compositions, and methods of preparation thereof | |
US20060159753A1 (en) | Matrix type sustained-release preparation containing basic drug or salt thereof | |
PT2079446E (en) | Paliperidone sustained release formulation | |
US20100015225A1 (en) | Solid dispersion of a neurokinin antagonist | |
US20180161269A1 (en) | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules | |
US10493067B2 (en) | Method of treating heart failure with preserved ejection fraction by administering milrinone | |
WO2008062470A2 (en) | Stabilized controlled release dosage form of gliclazide | |
US20090209587A1 (en) | Repaglinide formulations | |
TW202200123A (en) | Pharmaceutical composition with complex and preparation method therefor having a complex of an angiotensin II receptor antagonist metabolite and an NEP inhibitor | |
US20090028935A1 (en) | Carvedilol forms, compositions, and methods of preparation thereof | |
PT1178780E (en) | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations | |
US20050118256A1 (en) | Extended release alpha-2 agonist pharmaceutical dosage forms | |
WO2020037189A1 (en) | Formulations of ag10 | |
US20200078463A1 (en) | Composition having improved water solubility and bioavailability | |
US20230364075A1 (en) | Multiparticulate dosage forms comprising deutetrabenazine | |
WO2024100682A1 (en) | Sustained release composition of hydroxyzine and it's process | |
US20050059719A1 (en) | Solid dosage formulation containing a Factor Xa inhibitor and method | |
US10813916B2 (en) | Immediate release pharmaceutical composition of tizanidine | |
US20120329831A1 (en) | Pharmaceutical composition of donepezil | |
US20080182908A1 (en) | Pharmaceutical compositions comprising memantine |